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ICD-9 diabetes diagnosis (250.00 to 250.79) occurred
within one year of the patient’s transplant. We then used
a Kaplan-Meier-style non-parametric calculation to esti-
mate the average accumulated costs for patients with and
without NODM. RESULTS: Among the 4,515 trans-
plant recipients studied, 621 (13.7%) reported diabetes
diagnoses within the first year post-transplant. By the end
of the first post-transplant year, Medicare had paid
$35,288 for each non-diabetic recipient and an extra
$17,614 (P  0.001) for each of the NODM recipients.
By two years post-transplant, Medicare had paid an aver-
age $46,869 for each of the non-diabetic recipients and
an extra $26,032 for each of the NODM recipients (P 
0.001). CONCLUSIONS: Our 13.7% NODM exceeds
the 2% to 5% previously reported, and the extra
$26,032 is 55.5% above what Medicare paid for recipi-
ents without NODM. New immunosuppressives unasso-
ciated with NODM may generate substantial savings
worldwide.
PDB11
ECONOMIC OUTCOMES OF DIABETES AMONG 
AN EMPLOYED POPULATION
Leong SA1, Summers KH2, Birnbaum HG1, Kemner JE2,
Lentz EC1, Greenberg PE1
1Analysis Group/Economics, Cambridge, MA, USA; 2Eli Lilly and 
Company, Indianapolis, IN, USA
OBJECTIVES: The two major types of diabetes, Type I
and Type II diabetes, can have life-threatening complica-
tions, which often lead to significant adverse economic
consequences. This study investigates the extent to which
Type I and Type II diabetes impose significant financial
burdens on an employer METHODS: The data source is
a rich administrative claims database from a national,
Fortune 100 manufacturer. It includes all medical, phar-
maceutical, and disability claims for employees, spouses,
dependents, and retirees (n  100,000). The diabetes re-
search sample consists of individuals with at least two
medical and/or disability claims for diabetes or at least
one prescription drug claim for a hypoglycemic agent.
Resource utilization by diabetes patients, who are identi-
fied as either Type I or Type II diabetics, is contrasted
with that of matched samples from the employer’s overall
beneficiary population. RESULTS: Direct (medical and
pharmaceutical) and indirect (disability and sporadic ab-
senteeism) costs of Type I and Type II diabetes are ana-
lyzed. The total average per capita annual costs are
$2,612 for the Matched Type I Control sample compared
to $9,397 for Type I diabetics, and $3,432 for the
Matched Type II Control sample compared to $7,639 for
Type II diabetics. While Type I diabetics cost the em-
ployer more than Type II diabetics on average, the cost of
Type II diabetes patients, who were prescribed insulin,
exceeds the cost of Type I diabetes patients. Also, while
the costs of both types of diabetes are relatively high, less
than 50% of total medical costs for these patients are for
the treatment of diabetes or related co-morbid condi-
tions. CONCLUSIONS: Diabetes adds a significant fi-
nancial burden on the employer. The resources used by
both types of diabetics are substantial, not only for the
treatment of diabetes, but also for the treatment of re-
lated co-morbid conditions, as well as other conditions.
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OBJECTIVES: To conduct a pharmacoeconomic analysis
to estimate the potential cost avoidance due to reduced
rate of incidence of diabetes after weight-reduction ther-
apy in obese Chinese patients with impaired glucose tol-
erance (IGT). METHODS: The incidence of IGT-to-dia-
betes mellitus (DM) conversion of two hypothetical
cohorts of obese Chinese patients with IGT, either man-
aged with diet control (n  100) or diet control plus or-
listat (n  100), were projected over a two-year period.
The probabilities of IGT-to-DM progression in the or-
listat plus diet group and the diet only group were esti-
mated from a published study in a non-Chinese and a
westernized Chinese population, respectively. Direct medical
costs of management of type 2 diabetes were estimated
from a public budget perspective. RESULTS: The esti-
mated rates of IGT-to-DM conversion were 1.9% for the
orlistat plus diet group and 8% for the diet only group.
The total costs of DM management at the end of the first
and second years were estimated to be HK$8,187 and
HK$23,390 ($HK 7.8  $US 1) for the orlistat group. In
the diet only group, the costs of DM management were
HK$34,469 in year one and HK$100,123 in year two.
The cost avoidance associated with orlistat therapy were
calculated to be HK$26,282 and HK$75,092 per 100 pa-
tients at the end of the first and second years, respec-
tively. CONCLUSIONS: Results of the present study sug-
gest positive economic impacts of weight-reduction therapy
in a hypothetical Chinese population with IGT in the pre-
vention of type 2 diabetes.
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OBJECTIVES: Optimization of type 2 diabetes interven-
tion strategies in Germany based on stepwise prognoses
